Full-Time
Senior SAP Basis Integration Manager
Waters Corporation
10,001+ employees
Analytical instruments, software, and services provider
No salary listed
Franklin, MA, USA
In Person
 DevOps & Infrastructure (1) |
|---|
- 12+ years of SAP experience, including program leadership roles
- Strong SAP Basis background (installations, upgrades, migrations, performance tuning)
- Proven track record in ERP/SAP integration projects involving acquisitions or divestitures
- Advanced negotiation, conflict management, and influencing skills
- Ability to translate business strategy into functional objectives and integration plans
- Excellent communication and presentation abilities with executive audiences
- Bachelor’s degree in IT, Computer Science, Systems Engineering, or related field
- Lead planning and execution of SAP Basis integration activities for mergers and acquisitions
- Develop inventory of merged company assets across people, process, technology, and data (including boundary applications)
- Define and drive decisions on infrastructure harmonization, data migration, and system alignment
- Conduct gap analysis and map technologies to L1 and L2 capabilities
- Align IT Day 1 requirements while minimizing impact on Waters’ in-flight projects
- Develop milestone plans for Day 1 and post-Day 1 integration projects
- Partner with business and IT stakeholders to align merged company processes with Waters’ SAP S/4HANA platform
- Collaborate with SAP solution architects and functional leads to design migration roadmaps
- Establish criteria for system cloning vs. integration with timelines and roadmaps
- Drive alignment on interim and end-state blueprints with business stakeholders
- Experience with SAP S/4HANA preferred
Waters Corporation provides analytical system solutions, software, and services for scientists across biopharma, clinical research, forensics, life science research, food and beverage, and environmental sectors. Its products include high-performance analytical instruments like the BioAccord System, paired with software and ongoing support to enable precise, reproducible results. The company operates by selling instruments and software and offering maintenance and services to enhance user experience and reliability. Compared to competitors, Waters offers an integrated package of hardware, software, and service across multiple markets, focused on delivering accurate analyses and end-to-end workflow solutions rather than just standalone devices. Its goal is to unlock the potential of science by solving problems that affect human health and well-being.
Company Size
10,001+
Company Stage
IPO
Headquarters
Milford, Connecticut
Founded
1958
Simplify's Take
What believers are saying
- Q1 2026 organic growth 11% constant currency; raised full-year guidance to 6.5-8%.
- Acquired BD Biosciences unit exceeded revenue by $40M; targeting $55M cost synergies.
- China pharmaceutical revenue grew 50%+ targeting biotech CDMOs and emerging domestic companies.
What critics are saying
- Competitors release comparable MALS and blood culture systems within 12-18 months, eroding differentiation.
- $3.5B debt at 4.3-5.2% creates refinancing cliff 2027-2036 if growth slows.
- BD acquisition integration risks $55M synergy target; supply chain fragmentation could halve realized savings.
What makes Waters Corporation unique
- BD BACTEC FXI detects bloodstream infections 3 hours faster with automated blood volume measurement.
- omniDAWN MALS enables 4x faster large molecule analysis with 10x molar mass improvement.
- ARES-G3 Rheometer reduces testing times 80% while capturing 25,000 data points per second.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Waters Corporation who can refer or advise you
Benefits
Hybrid Work Options
Company News
Waters Corporation has launched the omniDAWN Multi-Angle Light Scattering Photometer, the first extended-range MALS detector designed for ultra high performance liquid chromatography workflows. The device features 18 detection angles and delivers chromatographic run times up to four times faster than conventional methods. The photometer extends UPLC-compatible sizing tenfold, from approximately 50 to 500 nanometres in radius, enabling characterisation of complex molecules including protein aggregates, viral vectors and lipid nanoparticles. It achieves a 10-fold improvement in absolute molar mass measurements whilst reducing sample consumption by 30–50% and solvent use by roughly 40%. The device integrates with Waters UPLC systems and is powered by ASTRA software, supporting analysis across drug discovery, development and quality control. The omniDAWN photometer will be available globally in summer 2026.
Waters Corporation has received FDA clearance for the Onclarity HPV Self-Collection Kit and approval for the BD Onclarity HPV Assay with extended genotyping for at-home use. The kit enables cervical cancer screening from home, addressing barriers that prevent many individuals from routine testing. Approximately 60% of cervical cancer cases occur in unscreened or under-screened individuals. The BD Onclarity HPV Assay is the only FDA-approved test identifying six individual HPV genotypes and three pooled groups, making it the most comprehensive screening tool available in the US. The kit will be available by prescription in coming months and is covered by private insurance, Medicaid and Medicare. Waters is establishing partnerships for broader nationwide access, with patients able to collect samples at home and mail them to laboratories for processing.
Paul Hastings advised underwriters including Barclays Capital, Citigroup Global Markets and J.P. Morgan Securities in a $3.5 billion senior notes offering by Augusta SpinCo Corporation, a Waters Corporation subsidiary. The SEC-registered offering comprises five tranches of senior notes maturing between 2027 and 2036, with interest rates ranging from 4.321% to 5.245%. The notes are guaranteed by Waters and certain subsidiaries. Partner Jeff Ramsay led the Paul Hastings team, which included partners Morgan Bale, Ismael Duran and Daniel Nicholas, along with several associates.
Waters Corporation (WAT), a leading scientific instruments manufacturer, is underperforming the Dow Jones Industrial Average significantly. The stock trades 28.8% below its 52-week high of $414.15 and has declined 22.3% year-to-date, compared to the Dow's 3.8% decline. The Milford, Massachusetts-based company, with a market cap of $28.9 billion, specialises in analytical technologies including liquid chromatography and mass spectrometry for pharmaceutical, life sciences and industrial applications. Despite reporting solid fourth-quarter results with revenue of $932 million, up 7% year-over-year, and adjusted earnings per share rising 10% to $4.53, investor sentiment has soured. Cautious first-quarter guidance and concerns over its acquisition of Becton Dickinson's biosciences unit, which is underperforming expectations, have weighed on the stock.
Waters Corporation reported Q4 revenues of $932.4 million, down 45.4% year on year, meeting analysts' expectations. The analytical instruments manufacturer delivered mixed results, with next quarter's revenue guidance exceeding expectations but earnings per share guidance falling short. The research tools and consumables sector reported a satisfactory Q4 overall, with the 10 tracked stocks beating revenue consensus estimates by 1.2%. However, share prices have struggled, declining 20.9% on average since latest earnings results. Founded in 1958, Waters develops analytical instruments, software and consumables for liquid chromatography, mass spectrometry and thermal analysis. CEO Udit Batra highlighted the company achieved high single-digit revenue growth and double-digit adjusted EPS growth in 2025, with momentum expected to continue into 2026.